Your browser doesn't support javascript.
loading
De novo mutations in regulatory elements in neurodevelopmental disorders.
Short, Patrick J; McRae, Jeremy F; Gallone, Giuseppe; Sifrim, Alejandro; Won, Hyejung; Geschwind, Daniel H; Wright, Caroline F; Firth, Helen V; FitzPatrick, David R; Barrett, Jeffrey C; Hurles, Matthew E.
Afiliação
  • Short PJ; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • McRae JF; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Gallone G; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Sifrim A; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Won H; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
  • Geschwind DH; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
  • Wright CF; Center for Autism Research and Treatment, Program in Neurobehavioral Genetics, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
  • Firth HV; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
  • FitzPatrick DR; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Barrett JC; Institute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Level 4, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK.
  • Hurles ME; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Nature ; 555(7698): 611-616, 2018 03 29.
Article em En | MEDLINE | ID: mdl-29562236
ABSTRACT
We previously estimated that 42% of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences. The role of de novo mutations in regulatory elements affecting genes associated with developmental disorders, or other genes, has been essentially unexplored. We identified de novo mutations in three classes of putative regulatory elements in almost 8,000 patients with developmental disorders. Here we show that de novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders. We identified a significant twofold enrichment of recurrently mutated elements. We estimate that, genome-wide, 1-3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism. Our findings represent a robust estimate of the contribution of de novo mutations in regulatory elements to this genetically heterogeneous set of disorders, and emphasize the importance of combining functional and evolutionary evidence to identify regulatory causes of genetic disorders.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sequências Reguladoras de Ácido Nucleico / Transtornos do Neurodesenvolvimento / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sequências Reguladoras de Ácido Nucleico / Transtornos do Neurodesenvolvimento / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido